Klonopin Half-Life: A Clinician’s Guide to Clonazepam Pharmacokinetics, Detection Windows, Daily Dosing, Withdrawal Timeline, and the Risks of Long-Term Use

What the klonopin half-life is in adults and special populations, how the long half-life shapes the medication’s clinical effect for panic disorder and seizures, when peak levels occur, how long klonopin stays in the system for drug testing, the implications of the half-life for daily dosing and tapering, and what the half-life means for dependence and withdrawal symptoms.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

The elimination half-life of klonopin (clonazepam) is 30 to 40 hours in healthy adults, with some studies showing a range of 19 to 60 hours depending on individual factors. This is one of the longest half-lives among the benzodiazepines, comparable to diazepam but without the active metabolites that extend diazepam’s effect even further. Peak plasma concentration after an oral dose is reached at 1 to 4 hours. Clonazepam is metabolised primarily by the CYP3A4 enzyme to inactive 7-amino-clonazepam, which is then excreted in urine. The long half-life means that steady-state plasma levels are not reached for 5 to 10 days of daily dosing, that twice-daily dosing produces less fluctuation than three-times-daily, and that the drug remains detectable in urine for 5 to 14 days after the last dose in chronic users. The long half-life makes clonazepam useful for sustained anxiolysis in panic disorder and for the prevention of withdrawal seizures, but it also produces a long withdrawal timeline that can extend for weeks to months. Patients tapering clonazepam need a slow schedule with small dose reductions every two to four weeks to avoid severe rebound symptoms.

What the klonopin half-life is and why it matters

The elimination half-life of klonopin (clonazepam) is one of the most clinically important properties of the medication and shapes nearly every aspect of how it is prescribed, dosed, and discontinued. The half-life refers to the time required for the plasma concentration of the drug to fall by 50 percent, and it determines how long the drug remains active in the body after a dose, how quickly steady-state is reached with daily dosing, how often the medication needs to be taken to maintain therapeutic levels, and how long the drug persists during a taper or after discontinuation. For clonazepam in healthy adults, the half-life is 30 to 40 hours, with a range of 19 to 60 hours depending on individual factors.

The long half-life makes clonazepam one of the most useful long-acting benzodiazepines in current psychiatric practice. The medication is widely prescribed for panic disorder, generalised anxiety, social anxiety, certain seizure disorders, and as a part of treatment for restless legs syndrome and rapid eye movement sleep behaviour disorder. The long half-life produces a sustained anxiolytic effect that can be achieved with once-daily or twice-daily dosing rather than the three- or four-times-daily dosing required by shorter-acting agents such as alprazolam. The sustained drug levels also produce a smoother clinical effect with less inter-dose breakthrough anxiety, which is particularly valuable in panic disorder where unpredictable anxiety peaks are the main therapeutic target.

The long half-life also has disadvantages and clinical implications that prescribers and patients should understand. Steady-state plasma levels take 5 to 10 days to develop after starting daily dosing, which is why the full therapeutic effect of a particular daily dose is not apparent until the second week of treatment. Dose adjustments take a similar 5 to 10 days to reach their new steady state, so dose titration is slow. The drug remains in the system for many days after discontinuation, which means that withdrawal symptoms are delayed but prolonged, and that drug interactions can persist for days after the medication is stopped.

Half-life details and pharmacokinetics

Clonazepam is absorbed from the gastrointestinal tract with peak plasma concentration at 1 to 4 hours after an oral dose. The drug has high oral bioavailability of approximately 90 percent, which is one of the highest among the benzodiazepines and contributes to the consistency of its effect. The medication has substantial lipid solubility and crosses the blood-brain barrier rapidly, producing onset of anxiolytic and anticonvulsant effects within 30 to 60 minutes of an oral dose. Peak effect typically occurs 1 to 2 hours after administration.

Distribution of clonazepam in the body follows a two-compartment model, with rapid distribution into well-perfused tissues including the brain followed by slower redistribution into adipose and muscle tissue. The volume of distribution is approximately 3 L/kg, indicating substantial tissue binding. Protein binding is high at approximately 85 percent, primarily to albumin. The free fraction available for pharmacological activity is small, which is one of the reasons that hypoalbuminaemia (low blood albumin) can produce unexpectedly strong effects from standard doses by increasing the free drug concentration.

Metabolism of clonazepam occurs primarily in the liver by the cytochrome P450 3A4 enzyme system, with smaller contributions from CYP2C19 and CYP2C9. The principal metabolite is 7-amino-clonazepam, which is pharmacologically inactive. Other minor metabolites include 7-acetamido-clonazepam and 3-hydroxy-clonazepam. The metabolites are conjugated to glucuronides and excreted in urine. Less than 0.5 percent of administered clonazepam is excreted unchanged in urine, which is part of why specific urine testing for the parent drug has limited sensitivity and most clinical drug testing detects the 7-amino metabolite.

The half-life of clonazepam is prolonged in several patient populations. Elderly patients have a half-life of 40 to 60 hours due to reduced hepatic metabolism. Patients with significant liver disease can have a half-life of 60 to 100 hours. Patients on strong CYP3A4 inhibitors including ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice in significant quantities can have substantially prolonged half-lives. Patients on strong CYP3A4 inducers including rifampin, carbamazepine, and phenytoin can have shortened half-lives and reduced plasma levels at standard doses. Patients with renal impairment do not have significantly altered clonazepam half-life because the parent drug is not significantly excreted by the kidneys.

Detection windows: how long does klonopin stay in your system?

Drug testing for clonazepam typically detects the 7-amino-clonazepam metabolite rather than the parent compound. Standard benzodiazepine immunoassays may have variable sensitivity for clonazepam compared to other benzodiazepines, which is one of the reasons specific testing for the 7-amino metabolite is used in forensic and clinical settings where clonazepam detection is specifically needed. The detection windows vary substantially by testing matrix and by duration of use.

Urine testing detects clonazepam (as the 7-amino metabolite) for 5 to 14 days after the last dose in chronic users, and for 2 to 7 days in occasional or single-dose users. The relatively long detection window reflects both the long half-life of the parent drug and the continued excretion of the metabolite for days after the parent drug is cleared. Hair testing can detect clonazepam use for up to 90 days in standard 1.5-inch hair samples. Oral fluid testing detects clonazepam for 1 to 5 days. Blood testing detects clonazepam for 1 to 2 days but is rarely used outside of acute clinical settings.

Factors that affect detection times include the dose (higher doses are detected longer), the duration of use (chronic use produces longer detection windows than single use), individual metabolism (slower metabolisers retain the drug longer), age (older patients have longer detection windows), body composition (substantial adipose tissue produces longer detection because clonazepam is lipid-soluble), hepatic function (impaired function prolongs detection), and concurrent medications that affect CYP3A4. Patients on clonazepam who are facing drug testing should be aware that the detection window is among the longest of any benzodiazepine.

Patients with a valid prescription for clonazepam who are facing employment drug testing should expect to test positive for benzodiazepines and should disclose the prescription to the medical review officer (MRO) when contacted. The MRO process verifies the prescription with the prescriber and pharmacy and reports the result to the employer as a verified prescription rather than as a positive test. The same process applies to all prescription benzodiazepines and produces no inappropriate employment consequences for legitimate prescription users.

Implications for dosing: how often should klonopin be taken?

The long half-life of clonazepam permits once-daily or twice-daily dosing for most adult patients. The typical starting dose for panic disorder is 0.25 mg twice daily or 0.5 mg once daily at bedtime, titrated upward over one to two weeks to a usual effective dose of 1 to 4 mg per day in divided doses. For seizure disorders, the starting dose is 1.5 mg per day in three divided doses, with maintenance at 2 to 8 mg per day. The maximum recommended daily dose is 20 mg in special circumstances under specialist supervision, though most patients respond at much lower doses.

Twice-daily dosing (typically morning and evening) is the most common pattern for panic disorder and produces relatively stable plasma levels throughout the day with mild fluctuation around mealtimes. Once-daily bedtime dosing is useful for patients whose anxiety symptoms are predominantly evening or sleep-related, and for patients who prefer simpler dosing schedules. Three-times-daily dosing is occasionally used for seizure disorders where more consistent plasma levels are required, but is generally not necessary for anxiety indications given the long half-life.

The take time of clonazepam doses can be matched to expected anxiety patterns. Patients with predominantly morning anxiety can take the larger dose in the morning. Patients with predominantly evening or pre-sleep anxiety can take the larger dose in the evening. Patients with panic attacks at specific predictable times (such as before social events or work meetings) can use a small additional dose 30 to 60 minutes before the trigger, though this approach risks reinforcing the pattern of using the medication situationally and is generally less effective than steady-state dosing combined with cognitive behavioural therapy.

Dose adjustments should anticipate the long half-life. A dose increase from 1 mg per day to 2 mg per day will reach its new steady state at 5 to 10 days, and the patient should be cautioned that effects will build over the first week rather than appearing immediately. The same long timeframe applies to dose reductions during taper, which is why tapers are slow and produce delayed rather than immediate withdrawal symptoms when each step is too aggressive.

Withdrawal timeline shaped by the half-life

The withdrawal timeline for clonazepam is shaped substantially by the long half-life. After the last dose, plasma levels fall by 50 percent at 30 to 40 hours, by 75 percent at 60 to 80 hours, and by 90 percent at 100 to 130 hours. Clinically significant blood levels can persist for 5 to 10 days, which is part of why acute withdrawal symptoms are delayed compared to shorter-acting benzodiazepines. The first withdrawal symptoms typically emerge 2 to 4 days after the last dose, peak at 5 to 14 days, and gradually subside over the following weeks to months.

The acute withdrawal symptoms include rebound anxiety often worse than the original presenting symptoms, insomnia and disrupted sleep, tremor, sweating, gastrointestinal upset, sensitivity to light and sound, mood instability, panic disorder symptoms even in patients who originally took the medication for other indications, and in severe cases withdrawal seizures and psychotic symptoms. The patient on long-term clonazepam who stops abruptly is at higher risk of seizures than the patient on shorter-acting benzodiazepines, because the slow fall in plasma levels means the brain has not had time to adapt by the time levels become critically low.

The protracted withdrawal syndrome is the most challenging aspect of clonazepam discontinuation for many long-term users. Symptoms including persistent anxiety, depression, cognitive difficulties, perceptual disturbances, and autonomic instability can persist for months to a year after the medication is stopped, even with a slow taper. The protracted syndrome reflects the slow recovery of GABA-A receptor function after sustained pharmacological enhancement and the up-regulation of glutamate excitatory neurotransmission that occurred during chronic use. Patients should be told to expect this phase and not to conclude that the medication is needed because symptoms persist.

The recommended taper schedule for clonazepam reflects the long half-life. For short-term users (less than six months), reductions of 0.125 to 0.25 mg every two to four weeks over a total of 2 to 6 months are typical. For long-term users (more than one year), reductions of 5 to 10 percent of the current dose every two to four weeks over 6 to 18 months are more appropriate. The Ashton manual provides detailed guidance on switching to diazepam for the taper (because diazepam has a similarly long half-life and is available in liquid form for fine dose adjustment), though clonazepam can also be tapered directly using its own range of tablet strengths.

Implications for dependence and tolerance

The long half-life of clonazepam produces a different dependence pattern than shorter-acting benzodiazepines such as alprazolam. The sustained plasma levels mean that patients on regular clonazepam do not experience the inter-dose anxiety peaks that often drive escalating use with alprazolam. The withdrawal between doses is mild or absent. This is one of the reasons clonazepam is sometimes preferred over alprazolam for patients who have shown problematic patterns with shorter-acting benzodiazepines: the steadier pharmacological profile produces less obvious dependence behaviour even when the underlying physiological dependence is similar.

Tolerance to the anxiolytic effect of clonazepam develops over two to four weeks of daily use, similar to other benzodiazepines. Tolerance to the anticonvulsant effect develops more slowly, which is one of the reasons clonazepam remains useful in epilepsy treatment for longer periods than would be expected based on anxiety experience. Tolerance to the sedative side effects develops quickly, which is why patients who feel initially sedated on the medication usually adjust within one to two weeks. The lack of obvious tolerance does not mean dependence is not occurring; the brain’s adaptation to the chronic drug presence proceeds even when the patient is not aware of it.

Physical dependence on clonazepam can develop in as little as two to four weeks of daily use and is essentially universal in patients on the medication for more than three months. The dependence is not the same as addiction, which includes the behavioural features of compulsive use, continued use despite consequences, and craving. Most patients on long-term clonazepam are physically dependent without meeting criteria for addiction, and the appropriate clinical response is careful taper rather than addiction treatment. Patients who do show addiction features need addiction medicine assessment in addition to taper support.

Drug interactions affected by the half-life

The long half-life of clonazepam means that drug interactions persist for days after the medication is stopped. Patients who stop clonazepam to start a medication that interacts with benzodiazepines (such as a strong CYP3A4 inhibitor that could elevate clonazepam levels) should wait at least 5 to 7 days for the drug to clear adequately. Patients who add a CYP3A4 inhibitor to existing clonazepam therapy should expect rising clonazepam levels over the first week of the new medication. Patients who add a CYP3A4 inducer should expect falling clonazepam levels over two to four weeks of the new medication, with possible need for clonazepam dose increase.

Combinations with other central nervous system depressants are the most clinically important drug interactions. Alcohol, opioids, other benzodiazepines, z-drugs, barbiturates, and sedating antihistamines all add to the CNS depressant effect and substantially increase respiratory depression risk. The combination of clonazepam with opioids is particularly dangerous and accounts for many benzodiazepine-related deaths in opioid overdose statistics. The FDA added a boxed warning to all benzodiazepines in 2016 specifically about the combination with opioids.

Other drug interactions of note include the SSRIs and SNRIs (which can mildly inhibit clonazepam metabolism), the antifungals (strong CYP3A4 inhibition), the macrolide antibiotics (CYP3A4 inhibition), the HIV protease inhibitors (potent CYP3A4 inhibition), and the antiepileptic medications that induce CYP3A4 (carbamazepine, phenytoin, phenobarbital). Patients on clonazepam should inform any new prescriber of the medication before starting any new drug, particularly any drug that affects hepatic metabolism.

Comparison with other benzodiazepine half-lives

The clonazepam half-life is notably long compared to other commonly prescribed benzodiazepines. Alprazolam (Xanax) has a half-life of 11 to 12 hours, which produces the rapid onset and shorter duration that has driven its widespread use for panic disorder but also produces the inter-dose withdrawal that makes it harder to discontinue. Lorazepam (Ativan) has a half-life of 10 to 20 hours and is metabolised by glucuronidation without active metabolites, making it useful in elderly patients and those with liver disease. Diazepam (Valium) has a similar parent-drug half-life of 20 to 100 hours but produces active metabolites that extend its effect substantially.

Benzodiazepine	Half-life (parent)	Active metabolites	Time to steady state
Alprazolam (Xanax)	11-12 hr	No significant	2-3 days
Lorazepam (Ativan)	10-20 hr	No	2-3 days
Clonazepam (Klonopin)	30-40 hr	No	5-10 days
Diazepam (Valium)	20-100 hr	Yes (nordiazepam, oxazepam)	5-14 days
Chlordiazepoxide (Librium)	24-48 hr	Yes (nordiazepam)	5-14 days
Oxazepam (Serax)	4-15 hr	No	1-2 days

The clinical implications of these differences include the choice of medication for specific indications (long-acting for panic disorder and seizure disorders, short-acting for procedural sedation), the patient population suitability (short-acting agents with no active metabolites preferred in elderly and liver-impaired patients), the taper strategy (long-acting agents permit slower withdrawal with less rebound), and the abuse potential (short-acting agents with rapid onset have higher abuse liability, which is one of the reasons alprazolam is particularly problematic in this regard).

Special populations: elderly, hepatic, paediatric

Elderly patients have substantially prolonged clonazepam half-life of 40 to 60 hours due to reduced hepatic metabolism, and the medication accumulates over a longer period before reaching steady state. Standard adult doses can produce excessive sedation, falls, cognitive impairment, and prolonged effects in older patients. The American Geriatrics Society Beers Criteria list clonazepam and all other benzodiazepines as medications to avoid in adults over 65 because of these risks. When clonazepam is prescribed in older patients, dose reduction by 50 percent and slower titration are appropriate.

Patients with hepatic impairment have prolonged clonazepam half-life because the medication depends on liver metabolism for clearance. Mild hepatic impairment produces modest prolongation (40 to 60 hours), but severe hepatic impairment (Child-Pugh class C) can extend the half-life to 80 to 100 hours or more. Dose reduction is appropriate in mild impairment, and alternative benzodiazepines without hepatic metabolism (lorazepam, oxazepam, temazepam) may be preferred in significant impairment.

Paediatric use of clonazepam includes the treatment of certain seizure disorders, particularly Lennox-Gastaut syndrome and absence seizures. The half-life in children is similar to that in adults at approximately 24 to 30 hours, slightly shorter than the adult range. Doses are calculated by weight, typically starting at 0.01 to 0.03 mg/kg per day in three divided doses, with maintenance at 0.1 to 0.2 mg/kg per day. The long half-life produces accumulation over the first week and dose increases should be slow with attention to side effects including drowsiness, ataxia, and behavioural changes.

When clonazepam use and drinking have become more than occasional

For readers who have been on clonazepam for months or years and are concerned about the dependence pattern or the difficulty of discontinuation, the long half-life is part of both the clinical advantage and the practical challenge of the medication. The same property that produces sustained anxiolysis and protects against breakthrough symptoms also means that withdrawal is delayed and prolonged, and that tapering is necessarily a slow process. Patients planning discontinuation should commit to a multi-month timeline and should have realistic expectations about the duration.

Heavy drinking is one of the substance use patterns that commonly coexists with long-term benzodiazepine use, often because alcohol provides additional anxiolysis that the patient feels they need or because the same anxiety that drove the original prescription continues to drive seeking of additional relief. The combination of regular clonazepam and regular drinking produces substantial cognitive impairment, profoundly impaired driving and operational function, and significant overdose risk. The cross-tolerance at the GABA-A receptor means that escalating one substance can produce withdrawal from the other in complicated ways.

Alcohol use disorder, the clinical term for problematic alcohol use, is defined by the DSM-5 criteria including drinking more than intended, unsuccessful efforts to cut down, craving, tolerance, withdrawal, and continued use despite consequences. Many people on long-term clonazepam also meet AUD criteria without recognising it because both substances have been integrated into their daily life. Phuket Island Rehab provides residential addiction medicine treatment for benzodiazepine dependence, alcohol use disorder, and dual diagnosis cases that include co-occurring anxiety, panic disorder, or other mental health conditions.

Summary

The klonopin half-life is 30 to 40 hours in healthy adults, with a range of 19 to 60 hours depending on individual factors and longer in elderly and hepatic-impaired patients. The long half-life makes the medication useful for sustained anxiolysis in panic disorder, generalised anxiety, and seizure prevention, with once-daily or twice-daily dosing producing relatively stable plasma levels. Steady state is reached at 5 to 10 days of consistent daily use, and the medication remains detectable in urine for 5 to 14 days after the last dose. The long half-life shapes the withdrawal timeline, with delayed but prolonged symptoms that can extend for months in long-term users. Tapering requires patience and small dose reductions every two to four weeks. The medication is one of the longer-acting benzodiazepines in current use, distinct from alprazolam and lorazepam but similar in pharmacokinetic profile to diazepam and chlordiazepoxide. As Dr. Ponlawat Pitsuwan summarises, “The long half-life of klonopin is both its principal clinical advantage and its main practical challenge. The sustained effect protects patients from breakthrough symptoms but the same property makes the medication slow to titrate and slow to discontinue. Patients on long-term therapy deserve a careful taper that respects the half-life and a realistic timeline for the work of coming off.”

Frequently asked questions

How long does klonopin stay in your body?

The elimination half-life of clonazepam is 30 to 40 hours, meaning plasma levels fall by 50 percent every 30 to 40 hours. The drug is largely eliminated by 5 to 7 half-lives, or 7 to 14 days. Detection in urine drug testing can extend to 14 days after the last dose in chronic users because the 7-amino-clonazepam metabolite is excreted for several days after the parent drug is cleared.

How long does it take klonopin to work?

Onset of anxiolytic and anticonvulsant effects after an oral dose typically occurs within 30 to 60 minutes, with peak effect at 1 to 2 hours. The full therapeutic effect at a particular daily dose develops over 5 to 10 days as steady-state plasma levels build up, which is why patients on a stable dose often notice continued improvement during the first week of treatment.

How often should klonopin be taken?

Once-daily or twice-daily dosing is sufficient for most adult indications because of the long half-life. Twice-daily morning-and-evening dosing is the most common pattern for panic disorder and produces stable plasma levels. Once-daily bedtime dosing works for patients with predominantly evening symptoms. Three-times-daily dosing is sometimes used for seizure disorders or in paediatric patients.

Can I drink alcohol while taking klonopin?

No. The combination of clonazepam and alcohol substantially increases sedation, respiratory depression risk, and accidental injury. Both substances enhance GABA-A receptor function and the combined effect is more than additive. Patients on clonazepam should generally avoid alcohol entirely, and any drinking that is occurring should be honestly disclosed to the prescriber so the safety implications can be discussed.

What happens if you suddenly stop taking klonopin?

Abrupt discontinuation after sustained daily use can produce withdrawal seizures, severe rebound anxiety and panic, insomnia, perceptual disturbances, and in rare cases delirium and death. The first withdrawal symptoms typically emerge 2 to 4 days after the last dose due to the long half-life, peak at 5 to 14 days, and gradually subside over weeks to months. A slow medical taper substantially reduces these risks.

Is klonopin longer-acting than xanax?

Yes. The clonazepam half-life of 30 to 40 hours is approximately three times longer than the alprazolam half-life of 11 to 12 hours. The longer half-life produces less inter-dose anxiety, less withdrawal between doses, and a smoother clinical profile, which is one of the reasons clonazepam is sometimes preferred over alprazolam for patients with panic disorder.

Sources

• U.S. Food and Drug Administration (FDA). Clonazepam (Klonopin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017533s053,020813s009lbl.pdf
• Ashton CH. Benzodiazepines: How they work and how to withdraw (The Ashton Manual). 2002. https://www.benzo.org.uk/manual/
• National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113
• American Geriatrics Society Beers Criteria Update Expert Panel. 2023 AGS Beers Criteria. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
• Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurologica Scandinavica. 2008;118(2):69-86. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0404.2008.01004.x
• U.S. Food and Drug Administration (FDA). Boxed warning on opioid and benzodiazepine combination. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or
• Substance Abuse and Mental Health Services Administration (SAMHSA). National helpline. https://www.samhsa.gov/find-help/national-helpline

klonopin, klonopin half-life, klonopin half life, clonazepam, benzodiazepine, long-acting benzodiazepine, half-life, elimination half-life, terminal half-life, pharmacokinetics, peak plasma concentration, bioavailability, lipid solubility, blood-brain barrier, volume of distribution, protein binding, albumin, CYP3A4, CYP2C19, CYP2C9, hepatic metabolism, 7-amino-clonazepam, glucuronide conjugation, GABA-A receptor, GABA, anxiolysis, anticonvulsant, sedation, panic disorder, generalised anxiety disorder, social anxiety, restless legs syndrome, REM sleep behaviour disorder, Lennox-Gastaut syndrome, absence seizures, drug, use, medication, system, long, treatment, body, half-life, dose, take, used, days, panic, side, hours, steady state, dosing, twice daily, once daily, three times daily, taper, tapering, withdrawal, withdrawal symptoms, withdrawal seizures, protracted withdrawal, rebound anxiety, physical dependence, tolerance, addiction, urine drug testing, hair test, oral fluid test, blood test, immunoassay, MRO, medical review officer, detection window, alprazolam, Xanax, lorazepam, Ativan, diazepam, Valium, chlordiazepoxide, Librium, oxazepam, Serax, temazepam, opioid, alcohol, z-drug, barbiturate, FDA, NICE, AGS Beers Criteria, Ashton manual, Heather Ashton, SAMHSA, Benzodiazepine Information Coalition, alcohol use disorder, AUD, DSM-5, dual diagnosis, Phuket Island Rehab, addiction medicine, mental health treatment, hepatic impairment, elderly patients, paediatric, Child-Pugh class C, ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit, rifampin, carbamazepine, phenytoin, SSRI, SNRI.